Immunostimulants drugs - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.64 [0.43, 0.95]< 10%3 studies (3/-)98.6 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 1.07 [0.73, 1.57]< 10%1 study (1/-)36.6 %highnot evaluable lowcrucial-
deaths 0.78 [0.58, 1.05]< 10%6 studies (6/-)95.0 %highnot evaluable lowcrucial-
clinical deterioration 0.72 [0.37, 1.43]< 158%2 studies (2/-)82.3 %highnot evaluable lowimportant-
clinical improvement 0.68 [0.21, 2.20]> 10%1 study (1/-)25.9 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 2.03 [0.17, 24.32]> 175%2 studies (2/-)71.0 %some concernnot evaluable moderateimportant-
clinical improvement (7-day) 1.91 [1.03, 3.53]> 10%1 study (1/-)98.0 %some concernnot evaluable moderateimportant-
death or ventilation 0.66 [0.46, 0.94]< 10%1 study (1/-)98.9 %some concernnot evaluable moderateimportant-
hospital discharge 1.48 [1.05, 2.09]> 10%1 study (1/-)98.6 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.99 [0.54, 1.81]< 10%1 study (1/-)51.3 %highnot evaluable lowimportant-
viral clearance 1.61 [0.61, 4.25]> 182%3 studies (3/-)83.1 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %some concernnot evaluable moderateimportant-
viral clearance by day 14 0.18 [0.00, 435.69]> 198%2 studies (2/-)34.4 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.78 [0.91, 3.47]> 169%3 studies (3/-)95.4 %highnot evaluable lowimportant-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 0.99 [0.17, 5.88]< 10%2 studies (2/-)50.5 %some concernnot evaluable moderateimportant-
adverse events 1.41 [0.74, 2.67]< 10%2 studies (2/-)14.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.